Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844856 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
A Phase 3 study of Complicated Intra-abdominal Infections, sponsored by Tetraphase Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 541
- Enrollment target
- 20
- Study locations
NCT01844856: Completed Phase 3 study of Complicated Intra-abdominal Infections, sponsored by Tetraphase Pharmaceuticals.
NCT01844856 is a Phase 3 study of Complicated Intra-abdominal Infections that has completed, run by Tetraphase Pharmaceuticals. The registered enrollment target is 541 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01844856, a Phase 3 study of Complicated Intra-abdominal Infections, has completed, sponsored by Tetraphase Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 541 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).
Primary Outcome
Clinical response was classified as cure (complete resolution or significant improvement of signs and symptoms of the index infection), failure (death related to complicated intra-abdominal infection \[cIAI\], unplanned surgical procedures or percutaneous drainage procedures, persisting or recurrent infection within the abdomen, postsurgical wound infection, or administration of effective concomitant antibacterial therapy), or indeterminate (outcome was neither cure nor failure, or assessment wa
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eravacycline
- DRUG Ertapenem
Study Locations (20)
California
- - Glendale
- - La Mesa
- - Los Angeles
- - Torrance
Ohio
- - Cleveland
- - Columbus
- - Weston
Alabama
- - Florence
- - Mobile
Massachusetts
- - Boston
- - Springfield
New Jersey
- - Camden
- - Teaneck
Illinois
- - Aurora
Indiana
- - Carmel
Minnesota
- - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 541 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
What the finished NCT01844856 record still lists
NCT01844856 is an interventional study that assigns participants to a tested intervention. The registered 541 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Complicated Intra-abdominal Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01844856 names 20 study sites across 12 states, led by California, Ohio, Alabama.
Frequently Asked Questions
What is clinical trial NCT01844856 about?
NCT01844856 is a clinical study titled "Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections". This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).
What is the current status of trial NCT01844856?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 541 participants. The study started on 2013-08. Estimated completion is 2014-08.
What conditions does trial NCT01844856 study?
This clinical trial studies the following conditions: Complicated Intra-abdominal Infections.
What interventions are being tested in trial NCT01844856?
The interventions under investigation include: Placebo (DRUG), Eravacycline (DRUG), Ertapenem (DRUG).
Who is sponsoring clinical trial NCT01844856?
This trial is sponsored by Tetraphase Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01844856 being conducted?
This trial has 20 study locations across Alabama, California, Illinois, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01844856's enrollment target sits among peer trials
541 694th of 2000 higher than 1,307 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia